NASDAQ:QDEL - Nasdaq - US2197981051 - Common Stock - Currency: USD
28.09
+0.31 (+1.12%)
The current stock price of QDEL is 28.09 USD. In the past month the price decreased by -21.69%. In the past year, price decreased by -29.14%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.96 | 223.47B | ||
ISRG | INTUITIVE SURGICAL INC | 67.35 | 184.36B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.74 | 150.72B | ||
SYK | STRYKER CORP | 29.95 | 139.34B | ||
MDT | MEDTRONIC PLC | 15.76 | 107.94B | ||
BDX | BECTON DICKINSON AND CO | 14.74 | 58.89B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.25 | 44.70B | ||
IDXX | IDEXX LABORATORIES INC | 38.88 | 35.45B | ||
RMD | RESMED INC | 25.98 | 34.64B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.24 | 31.33B | ||
DXCM | DEXCOM INC | 43.43 | 28.10B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.94 | 23.53B |
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
QUIDELORTHO CORP
9975 Summers Ridge Road
San Diego CALIFORNIA 92121 US
CEO: Douglas C. Bryant
Employees: 7100
Company Website: https://www.quidelortho.com/
Investor Relations: https://ir.quidel.com/
Phone: 18585521100
The current stock price of QDEL is 28.09 USD. The price increased by 1.12% in the last trading session.
The exchange symbol of QUIDELORTHO CORP is QDEL and it is listed on the Nasdaq exchange.
QDEL stock is listed on the Nasdaq exchange.
15 analysts have analysed QDEL and the average price target is 54.35 USD. This implies a price increase of 93.49% is expected in the next year compared to the current price of 28.09. Check the QUIDELORTHO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUIDELORTHO CORP (QDEL) has a market capitalization of 1.89B USD. This makes QDEL a Small Cap stock.
QUIDELORTHO CORP (QDEL) currently has 7100 employees.
QUIDELORTHO CORP (QDEL) has a resistance level at 28.1. Check the full technical report for a detailed analysis of QDEL support and resistance levels.
The Revenue of QUIDELORTHO CORP (QDEL) is expected to decline by -2.54% in the next year. Check the estimates tab for more information on the QDEL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QDEL does not pay a dividend.
QUIDELORTHO CORP (QDEL) will report earnings on 2025-05-07, after the market close.
The PE ratio for QUIDELORTHO CORP (QDEL) is 15.18. This is based on the reported non-GAAP earnings per share of 1.85 and the current share price of 28.09 USD. Check the full fundamental report for a full analysis of the valuation metrics for QDEL.
The outstanding short interest for QUIDELORTHO CORP (QDEL) is 6.06% of its float. Check the ownership tab for more information on the QDEL short interest.
ChartMill assigns a fundamental rating of 3 / 10 to QDEL. Both the profitability and financial health of QDEL have multiple concerns.
Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 1.85. The EPS decreased by -55.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -31.94% | ||
ROE | -68.76% | ||
Debt/Equity | 0.72 |
ChartMill assigns a Buy % Consensus number of 76% to QDEL. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 29.93% and a revenue growth -2.54% for QDEL